GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cann Group Ltd (ASX:CAN) » Definitions » Common Stock

Cann Group (ASX:CAN) Common Stock : A$186.16 Mil (As of Dec. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Cann Group Common Stock?

Cann Group's quarterly common stock increased from Dec. 2023 (A$182.38 Mil) to Jun. 2024 (A$182.90 Mil) and increased from Jun. 2024 (A$182.90 Mil) to Dec. 2024 (A$186.16 Mil).

Cann Group's annual common stock increased from Jun. 2022 (A$169.43 Mil) to Jun. 2023 (A$177.37 Mil) and increased from Jun. 2023 (A$177.37 Mil) to Jun. 2024 (A$182.90 Mil).


Cann Group Common Stock Historical Data

The historical data trend for Cann Group's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cann Group Common Stock Chart

Cann Group Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Common Stock
Get a 7-Day Free Trial 97.14 149.67 169.43 177.37 182.90

Cann Group Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 177.59 177.37 182.38 182.90 186.16

Cann Group Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Cann Group Business Description

Traded in Other Exchanges
Address
262-276 Lorimer Street, Ground Floor, Port Melbourne, VIC, AUS, 3207
Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes under the licenses and permits issued to the company, the development and manufacture (via third-party arrangements) of finished product formulations. Geographically, the company operates in Europe and Australia. The company derives maximum revenue from Australia.